<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823026</url>
  </required_header>
  <id_info>
    <org_study_id>H-18065635-YIC</org_study_id>
    <nct_id>NCT04823026</nct_id>
  </id_info>
  <brief_title>Host RNA Profiles to Detect Infections in Young Infants</brief_title>
  <acronym>CHILD_YIC</acronym>
  <official_title>Host RNA Profiles to Detect Infections in Young Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to identify and test host RNA expression profiles as markers for infections&#xD;
      in young infants. Preliminary studies have shown high sensitivity and specificity for the&#xD;
      discrimination of bacterial from non-bacterial infections in children, but the method has&#xD;
      only been investigated in a limited number of young infants. The study aims to include 65&#xD;
      young infants with serious bacterial infections. The samples will be analysed by RNA&#xD;
      sequencing. New diagnostic tools may help reduce unnecessary antibiotic treatment, antibiotic&#xD;
      resistance, side-effects, hospitalisation and invasive procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Infections in young infants is a challenge as 1) it is often not possible to distinguish&#xD;
      serious bacterial infection (SBI) from viral infection by clinical appearance alone, 2) a&#xD;
      causative organism is often not identified and 3) due to relatively low sensitivity and&#xD;
      specificity of current biomarkers. The consequence is overtreatment with antibiotics being&#xD;
      prescribed to as many as 50% of febrile young infants presenting to emergency departments.&#xD;
      However, the majority of these children does not have a bacterial infection. Host RNA&#xD;
      expression profiling has shown high sensitivity and specificity for discriminating bacterial&#xD;
      from non-bacterial infections in preliminary studies of febrile young infants.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      A prospective multicentre observational study including young infants admitted and evaluated&#xD;
      due to suspected infection at the 4 paediatric acute care units in the Capital Region of&#xD;
      Denmark (Rigshospitalet, Hvidovre Hospital, Herlev Hospital, Nordsjællands Hospital -&#xD;
      Hillerød). Whole blood will be collected in PAXgene blood RNA tubes and analysed by RNA&#xD;
      sequencing at the Centre for Genomic Medicine, Rigshospitalet. Host RNA expression profiles&#xD;
      will be identified in a discovery cohort and the diagnostic performance will be tested in a&#xD;
      validation cohort. A control group of healthy and afebrile young infants will be included.&#xD;
&#xD;
      Time frames:&#xD;
&#xD;
      Patient recruiting: May 15th 2020 to February 28th 2022. Sample analysis (RNA sequencing):&#xD;
      March 1st 2022 to August 31st 2022.&#xD;
&#xD;
      Perspectives:&#xD;
&#xD;
      New molecular-based diagnostic tools complementary to conventional methods may optimise&#xD;
      infection management in young infants by improving early diagnostics and allowing early&#xD;
      modification of antibiotic treatment. This will reduce antibiotic resistance, side effects,&#xD;
      unnecessary hospitalisation and invasive procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Host RNA expression profiles</measure>
    <time_frame>21 months</time_frame>
    <description>To identify specific host RNA expression profiles in whole blood in response to bacterial infections in young infants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Application of known host RNA profiles</measure>
    <time_frame>21 months</time_frame>
    <description>To test host RNA profiles published in other studies, e.g. based on the genes IFI44L and FAM89A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time study</measure>
    <time_frame>21 months</time_frame>
    <description>To investigate the change in host RNA expression over time during an infection period</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Bacterial Infections</condition>
  <condition>Urinary Tract Infections</condition>
  <condition>Sepsis</condition>
  <condition>Fever</condition>
  <condition>Viral Infection</condition>
  <condition>Infant, Newborn, Disease</condition>
  <condition>Bacteremia</condition>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>70 young infants with proven bacterial infection.&#xD;
Interventions:&#xD;
Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a &quot;Discovery Cohort&quot; (identification of diagnostic RNA profiles) or a &quot;Validation Cohort&quot; (validation of the identified RNA profiles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>70 young infants with non-bacterial infection.&#xD;
Interventions:&#xD;
Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a &quot;Discovery Cohort&quot; (identification of diagnostic RNA profiles) or a &quot;Validation Cohort&quot; (validation of the identified RNA profiles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>30 young infants without infection.&#xD;
Interventions:&#xD;
Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a &quot;Discovery Cohort&quot; (identification of diagnostic RNA profiles) or a &quot;Validation Cohort&quot; (validation of the identified RNA profiles).</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All included young infants will have 0.50 - 2.50 ml whole blood drawn into PAXgene blood RNA&#xD;
      tubes (Qiagen®) along with routine blood tests within 48 hours of admission. Host RNA&#xD;
      expression profiling (whole transcriptome profiling) by RNA sequencing will be performed at&#xD;
      the Centre for Genomic Medicine, Rigshospitalet.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Young infants suspected of infection and admitted to one of the 4 paediatric departments in&#xD;
        the Capital Region of Denmark.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 0-3 months&#xD;
&#xD;
          2. admitted from home&#xD;
&#xD;
          3. suspected of infection&#xD;
&#xD;
          4. having routine blood sampling done&#xD;
&#xD;
          5. gestational age or corrected gestational age greater than or equal to 37+0&#xD;
&#xD;
          6. informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. not possible to draw blood tests&#xD;
&#xD;
          2. withdrawal of consent&#xD;
&#xD;
          3. sampling &gt;48 hours after admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kia Hee Schultz Dungu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrikka Nygaard, Ass Prof PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kia Hee Schultz Dungu, MD</last_name>
    <phone>+45 22645782</phone>
    <email>kia.hee.schultz.dungu@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrikka Nygaard, Ass Prof PhD</last_name>
    <phone>+45 35459761</phone>
    <email>Ulrikka.Nygaard@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Paediatrics and Adolescent Medicine, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kia S Hee Schultz Dungu, MD</last_name>
      <phone>+45 22645782</phone>
      <email>kia.hee.schultz.dungu@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ulrikka Nygaard, MD, PhD</last_name>
      <phone>+4535459761</phone>
      <email>Ulrikka.Nygaard@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics and Adolescent Medicine, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Samsø Schmidt, MD, PhD</last_name>
      <email>lisbeth.samsoe.schmidt@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics and Adolescent Medicine, Nordsjællands Hospital - Hillerød</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Peter Glenthøj, MD, PhD</last_name>
      <email>jonathan.peter.glenthoej.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Inger Merete Jørgensen, MD, PhD</last_name>
      <email>inger.merete.joergensen@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics, Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Cortes, Professor</last_name>
      <email>Dina.Cortes@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Allan Bybeck Nielsen, MD</last_name>
      <email>Allan.Bybeck.Nielsen@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Kia Hee Schultz Dungu</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

